Back to Agenda
Preference Studies in Regulatory and Payers' Decisions: Are We Ready?
Session Chair(s)
Francesco Pignatti, MD
Scientific Adviser for Oncology
European Medicines Agency, Netherlands
Isabelle Huys, PharmD, PhD, MPharm
Professor
KU Leuven, Belgium
The ICH has announced upcoming guidance development on patient preference studies. This session brings together different stakeholders to discuss the state of play and recommendations for patient preference studies in the regulatory and health technology decision context. IN particular, the session focuses on the role of preference studies in different decisions, methodological challenges and opportunities, and expectations from the patient community for inclusion of preference studies in regulatory submissions.
Speaker(s)
![Jorien Veldwijk, PhD, MSc](/_Images/member/Generic_Image_Missing-Profile.jpg)
Patient Preferences Along the Drug Lifecycle
Jorien Veldwijk, PhD, MSc
Erasmus University Rotterdam, Netherlands
Should Patient Preferences Be Required in Drug Applications?
Antonella Cardone
Cancer Patients Europe, Belgium
Director
Challenges and Opportunities from an Industry Perspective
Sheila Dickinson, MSc
Novartis Pharma AG, Switzerland
Global Benefit-Risk Lead
Panelist
Irina Cleemput, PhD
Belgian Health Care Knowledge Centre (KCE), Belgium
Scientific Programme Director
Panelist
Douwe Postmus, PhD, MSc
University Medical Center Groningen & EMA, Netherlands
Assistant Professor & Seconded National Expert
Panelist
Robert Sauermann, DrMed
Austrian Federation of Social Insurances, Austria
Deputy Head of Department of Pharmaceutical Affairs
Have an account?